Ono Pharmaceutical Co Stock Fundamentals
| OPHLY Stock | USD 3.59 0.09 2.45% |
Ono Pharmaceutical Co fundamentals help investors to digest information that contributes to Ono Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Ono Pink Sheet. The fundamental analysis module provides a way to measure Ono Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ono Pharmaceutical pink sheet.
Ono |
Ono Pharmaceutical Co Company Return On Equity Analysis
Ono Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Ono Pharmaceutical Return On Equity | 0.16 |
Most of Ono Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ono Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Ono Pharmaceutical Co has a Return On Equity of 0.1605. This is 100.67% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The return on equity for all United States stocks is 151.77% lower than that of the firm.
Ono Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ono Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Ono Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ono Pharmaceutical competition to find correlations between indicators driving Ono Pharmaceutical's intrinsic value. More Info.Ono Pharmaceutical Co is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.75 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Ono Pharmaceutical Co is roughly 1.33 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Ono Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Ono Pharmaceutical's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Ono Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ono Pharmaceutical's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ono Pharmaceutical could also be used in its relative valuation, which is a method of valuing Ono Pharmaceutical by comparing valuation metrics of similar companies.Ono Pharmaceutical is currently under evaluation in return on equity category among its peers.
Ono Fundamentals
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 11.13 B | |||
| Shares Outstanding | 1.47 B | |||
| Shares Owned By Institutions | 0.03 % | |||
| Price To Earning | 18.66 X | |||
| Price To Book | 2.34 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 361.36 B | |||
| Gross Profit | 267.85 B | |||
| EBITDA | 123.45 B | |||
| Net Income | 80.52 B | |||
| Cash And Equivalents | 136.18 B | |||
| Cash Per Share | 92.88 X | |||
| Total Debt | 8.65 B | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 4.16 X | |||
| Book Value Per Share | 491.93 X | |||
| Cash Flow From Operations | 61.83 B | |||
| Earnings Per Share | 0.58 X | |||
| Number Of Employees | 3.69 K | |||
| Beta | 0.26 | |||
| Market Capitalization | 10.55 B | |||
| Total Asset | 739.2 B | |||
| Retained Earnings | 466.64 B | |||
| Working Capital | 163.56 B | |||
| Current Asset | 218.78 B | |||
| Current Liabilities | 55.22 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.82 % | |||
| Net Asset | 739.2 B | |||
| Last Dividend Paid | 28.0 |
About Ono Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ono Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ono Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ono Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company was founded in 1717 and is headquartered in Osaka, Japan. Ono Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 3687 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ono Pink Sheet Analysis
When running Ono Pharmaceutical's price analysis, check to measure Ono Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ono Pharmaceutical is operating at the current time. Most of Ono Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Ono Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ono Pharmaceutical's price. Additionally, you may evaluate how the addition of Ono Pharmaceutical to your portfolios can decrease your overall portfolio volatility.